Current adenosinergic therapies: what do cancer cells stand to gain and lose?
A key objective in immuno-oncology is to reactivate the dormant immune system and
increase tumour immunogenicity. Adenosine is an omnipresent purine that is formed in …
increase tumour immunogenicity. Adenosine is an omnipresent purine that is formed in …
Structural insight into CD20/CD3-bispecific antibodies by molecular modeling
Abstract Non-Hodgkin's Lymphoma (NHL) remains a significant challenge in hematology,
with chemotherapy and radiation therapy as conventional treatment options, albeit with …
with chemotherapy and radiation therapy as conventional treatment options, albeit with …
How do modulators affect the orthosteric and allosteric binding Pockets?
Allosteric modulators (AMs) that bind allosteric sites can exhibit greater selectivity than the
orthosteric ligands and can either enhance agonist-induced receptor activity (termed …
orthosteric ligands and can either enhance agonist-induced receptor activity (termed …
Synthesis, QSAR modeling, and molecular docking of novel fused 7‐deazaxanthine derivatives as adenosine A2A receptor antagonists
Predictive QSAR models for the search of new adenosine A2A receptor antagonists were
developed by using OCHEM platform. The predictive ability of the regression models has …
developed by using OCHEM platform. The predictive ability of the regression models has …
The Impact of Allosteric Modulators on The Orthosteric and Allosteric Binding Pockets
CJ Chen - 2022 - search.proquest.com
Allosteric modulators (AM) that bind allosteric sites can exhibit greater selectivity than the
orthosteric ligands and can either enhance agonist-induced receptor activity (termed …
orthosteric ligands and can either enhance agonist-induced receptor activity (termed …